跳到正文
原文
Medical Xpress·· 2026-10-15AI 评分52

研究表明:催乳素药物卡麦角林可能降低产后女性乳腺癌风险

Lactation drug could reduce breast cancer risk after childbirth, study suggests

AI 导读

一项在Cancer Discovery上发表的研究分析了超过15万人的健康记录,发现产后使用卡麦角林抑制泌乳的女性患乳腺癌风险降低了约70%。动物实验也印证了这一发现,研究人员目前正在通过临床试验验证该药物在人体中的疗效,有望为高危女性提供新的预防策略。

正文
new mum
Credit: Pixabay/CC0 Public Domain

An international team of scientists has found that a lactation drug could reduce the risk of breast cancer in mothers after childbirth. Cabergoline, a medication used to stop milk production after pregnancy loss or when breastfeeding is not possible, is generally well tolerated by patients with few side effects. But it may also offer unexpected benefits.

The study, published in Cancer Discovery, analyzed health records from Spain and Norway, including more than 150,000 women with information on whether they had used cabergoline.

Women who had the medication to suppress milk production were around 70% less likely to develop breast cancer in the years that followed, compared with those who did not receive cabergoline.

This finding mirrored what the researchers found in mice. They tested a single dose of cabergoline in mice carrying BRCA1 and TP53 mutations, which are associated with aggressive forms of breast cancer, and tumor incidence rates fell by about half.

"Breast cancer is the leading cause of cancer-related death among younger women, and the majority of these cancers occur during the years after pregnancy," said study co-lead Dr. Christopher Maxwell, professor in UBC's faculty of medicine and investigator at BC Children's Hospital Research Institute.

"This is particularly true for women at high risk of breast cancer. But our findings suggest there may be an opportunity to reduce that risk with an existing drug by helping the breast complete a natural process that happens after breastfeeding ends."

Like a fruit tree preparing for winter

After a woman stops breastfeeding, the breast undergoes a major cleanup process called "involution."

Maxwell likened it to a fruit tree. In spring and summer, the tree grows branches and produces blossoms and eventually fruit. Once the fruit is gone, the tree sheds what it no longer needs and prepares for the next season.

Similarly, during pregnancy, hormone levels rise and the milk-producing structures within the breast branch out, creating a 'ductal tree.' But once breastfeeding ends, those cells are no longer needed and the breast undergoes involution to remove excess tissue.

"We think of involution as the breast's version of winter," said Maxwell. "It's a period when structures that were needed for pregnancy and breastfeeding reset for the future."

But the researchers found that this cleanup process can be incomplete in the experimental mice, leaving behind cells that may become cancerous.

Cabergoline appears to help complete that transition by accelerating the breast's natural post-weaning process. In mouse studies, it reduced potentially precancerous tissue, shrank the ductal area, reduced cell growth, and boosted immune cells responsible for clearing damaged cells.

Clinical trial in the works

With one in eight women in Canada developing breast cancer in their lifetime, the researchers say new prevention strategies are urgently needed.

"We think the period after breastfeeding is an important window for prevention," said study co-lead Dr. Jesús Perez-Losada, a researcher at the Cancer Research Center, a joint institute of the Spanish National Research Council and the University of Salamanca.

"There is a unique opportunity to target involution, the natural process that begins after weaning. This is not about changing a woman's breastfeeding plans; any preventive intervention would be considered only after breastfeeding has ended."

The next step for the researchers is to test cabergoline in clinical trials and determine whether the benefits observed in mice can be confirmed in people. The multinational research team aims to conduct a clinical trial spanning multiple countries.

Women with a BRCA1 mutation will be recruited through high-risk clinics and will choose how long they want to breastfeed. After weaning, they will receive either cabergoline or a placebo while researchers monitor biological markers linked to future breast cancer risk.

It's a promising avenue because current preventive measures for women at high risk include hormone therapy or surgery, both of which can have significant physical and emotional side effects.

If successful in clinical trials, the drug's existing approval by regulatory agencies including Health Canada and the European Medicines Agency could accelerate its path to use as a breast cancer prevention strategy.

Publication details

Cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland Involution in Brca1-Mutant Mice and Is Associated with Reduced Risk in Younger Women, Cancer Discovery (2026). DOI: 10.1158/2159-8290.CD-26-0187

Journal information: Cancer Discovery

Key medical concepts

Breast Cancer

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Lactation drug could reduce breast cancer risk after childbirth, study suggests (2026, October 15) retrieved 15 October 2026 from https://medicalxpress.com/news/2026-10-lactation-drug-breast-cancer-childbirth.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com